Search Results - "Kaspers, S."

Dephosphocholination by Legionella effector Lem3 functions through remodelling of the switch II region of Rab1b by Kaspers, Marietta S., Pogenberg, Vivian, Pett, Christian, Ernst, Stefan, Ecker, Felix, Ochtrop, Philipp, Groll, Michael, Hedberg, Christian, Itzen, Aymelt

“…Bacterial pathogens often make use of post-translational modifications to manipulate host cells. Legionella pneumophila , the causative agent of Legionnaires…”
Get full text

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1) by Pieber, T. R., Famulla, S., Eilbracht, J., Cescutti, J., Soleymanlou, N., Johansen, O. E., Woerle, H. J., Broedl, U. C., Kaspers, S.

“…Aims To investigate the pharmacodynamics, efficacy and safety of empagliflozin as adjunct to insulin in patients with type 1 diabetes. Methods A total of 75…”
Get full text

Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial by Laffel, L. M. B., Tamborlane, W. V., Yver, A., Simons, G., Wu, J., Nock, V., Hobson, D., Hughan, K. S., Kaspers, S., Marquard, J.

“…Aims To assess the pharmacokinetic and pharmacodynamic profile of a single dose of empagliflozin in young people with Type 2 diabetes to identify the…”
Get full text

Monoclonal Anti-AMP Antibodies Are Sensitive and Valuable Tools for Detecting Patterns of AMPylation by Höpfner, Dorothea, Fauser, Joel, Kaspers, Marietta S., Pett, Christian, Hedberg, Christian, Itzen, Aymelt

“…AMPylation is a post-translational modification that modifies amino acid side chains with adenosine monophosphate (AMP). Recently, a role of AMPylation as a…”
Get full text

Natural killer cells in patients with severe chronic fatigue syndrome by Brenu, E W, Hardcastle, S L, Atkinson, G M, van Driel, M L, Kreijkamp-Kaspers, S, Ashton, K J, Staines, D R, Marshall-Gradisnik, S M

“…Maintenance of health and physiological homeostasis is a synergistic process involving tight regulation of proteins, transcription factors and other molecular…”
Get full text

Monoclonal Anti-AMP Antibodies Are Sensitive and Valuable Tools for Detecting Patterns of AMPylation by Höpfner, Dorothea, Fauser, Joel, Kaspers, Marietta S., Pett, Christian, Hedberg, Christian, Itzen, Aymelt

Get full text

PIH63 The KIGS Quality Insight Program Assessing the Quality of Care for Short Children Treated with Growth Hormone Using the Output from a Large Pharmaco-Epidemiological Survey by Kaspers, S, Ranke, M, Loftus, J, Wollmann, H, Doerr, H.G

Get full text

PIH67 Successful Development of Annual and Long Term Prediction Models to Estimate Height Outcome following Growth Hormone (GH) Therapy in Children Using Data from KIGS – A Large Pharmacoepidemiological Survey by Loftus, J, Ranke, M, Lindberg, A, Brosz, M, Kaspers, S, Wollmann, H, Koltowska-Haggstrom, M, Roelants, M

Get full text

Impact of overweight on effectiveness of treatment with human growth hormone in growth hormone deficient children: analysis of German KIGS data by Reinehr, T, Bechtold-Dalla Pozza, S, Bettendorf, M, Doerr, H-G, Gohlke, B, Hauffa, B P, Kaspers, S, Land, C, Mehls, O, Schwab, K-O, Stahnke, N, Ranke, M B

“…We hypothesized that overweight children with growth hormone deficiency (GHD) demonstrate a lower response to growth hormone (GH) as a result of a…”
Get more information

P298 L’inhibition du cotransporteur sodium-glucose de type 2 (SGLT2) par l’empagliflozine réduit la microalbuminurie chez les patients atteints de diabète de type 2 by Cherney, D, Von Eynatten, M, Lund, S, Kaspers, S, Crowe, S, Woerle, H.J, Hach, T

“…Introduction L’empagliflozine réduit le taux d’HbA1c, la pression artérielle (PA) et le poids chez les patients diabétiques de type 2 (DT2). Son effet…”
Get full text

Legionella effector AnkX displaces the switch II region for Rab1b phosphocholination by Ernst, Stefan, Ecker, Felix, Kaspers, Marietta S, Ochtrop, Philipp, Hedberg, Christian, Groll, Michael, Itzen, Aymelt

“…The causative agent of Legionnaires disease, , translocates the phosphocholine transferase AnkX during infection and thereby posttranslationally modifies the…”
Get full text

Is the response to growth hormone in short children born small for gestational age dependent on genetic or maternal factors? by Mehls, Otto, Lindberg, A, Bettendorf, M, Doerr, H-G, Hauffa, B P, Kaspers, S, Rohrer, T, Stahnke, N, Ranke, M B

“…We investigated whether genetic or maternal/environmental risk factors for being born small for gestational age (SGA), e.g. Silver-Russell syndrome, congenital…”
Get more information

4881Empagliflozin reduces mortality in analyses adjusted for control of blood pressure, low density lipoprotein cholesterol and HbA1c over time by Zinman, B., Mathieu, C., Kaspers, S., Mattheus, M., Woerle, H.J., Fitchett, D.

Get full text

EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE by Fitchett, D., Inzucchi, S., Sambevski, S., Kaspers, S., Pfarr, E., George, J., Zinman, B.

Get full text

P5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial by McGuire, D K, Zinman, B, Inzucchi, S E, Anker, S D, Wanner, C, Kaspers, S, George, J T, Elsasser, U, Woerle, H J, Lund, S S, Fitchett, D

Get full text

P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease by McGuire, D, Zinman, B, Inzucchi, S E, Anker, S D, Wanner, C, Kaspers, S, Von Eynatten, M, Johansen, O.-E, Elsasser, U, Pocock, S, Fitchett, D, Jamal, W, Hantel, S, Lund, S S

“…Abstract Background and aims The EMPA-REG OUTCOME trial included patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular (CV)…”
Get full text

EMPAGLIFLOZIN (EMPA) REDUCES MORTALITY IN ANALYSES ADJUSTED FOR CONTROL OF BLOOD PRESSURE (BP), LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) AND HBA1C OVER TIME by Fitchett, D., Mathieu, C., Kaspers, S., Mattheus, M., Woerle, H., Zinman, B.

Get full text

Effect of Soy Protein Containing Isoflavones on Cognitive Function, Bone Mineral Density, and Plasma Lipids in Postmenopausal Women: A Randomized Controlled Trial by Kreijkamp-Kaspers, Sanne, Kok, Linda, Grobbee, Diederick E, de Haan, Edward H. F, Aleman, André, Lampe, Johanna W, van der Schouw, Yvonne T

“…CONTEXT Postmenopausal estrogen therapy has been posited to have some beneficial effects on aging processes, but its use has risks. Isoflavones, estrogenlike…”
Get full text

Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial by Hamilton, A., Fitchett, D., Zinman, B., Inzucchi, S., Wanner, C., Anker, S., Pocock, S., Kaspers, S., Mattheus, M., Vedin, O., Hantel, S., Lund, S.

Get full text

PDB62 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN JAPAN BASED ON RESULTS FROM THE SUBGROUP ANALYSIS OF ASIAN PATIENTS IN THE EMPA-REG OUTCOME TRIAL by Kaku, K., Haneda, M., Sakamaki, H., Yasui, A., Murata, T., Ustyugova, A.V., Chin, R., Hirase, T., Shibahara, T., Hayashi, N., Kansal, A., Kaspers, S., Okamura, T.

Get full text